Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 32, 2015 - Issue 7
Submit an article Journal homepage
271
Views
3
CrossRef citations to date
0
Altmetric
Late effects

Secondary Solid Malignancies After High-Grade Glioma Treatment in Pediatric Patients

Michael KarremannDepartment of Pediatric and Adolescent Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, GermanyCorrespondence[email protected]
,
Marion HoffmannDivision of Pediatric Hematology and Oncology, Department of Child and Adolescent Health, University Medical Center Göttingen, Göttingen, Germany
,
Martin BeneschDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University Graz, Graz, Austria
,
Robert KwiecienInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany
,
André O. von BuerenDivision of Pediatric Hematology and Oncology, Department of Child and Adolescent Health, University Medical Center Göttingen, Göttingen, Germany
&
Christof M. KrammDivision of Pediatric Hematology and Oncology, Department of Child and Adolescent Health, University Medical Center Göttingen, Göttingen, Germany
Pages 467-473 | Received 16 Apr 2015, Accepted 09 May 2015, Published online: 03 Aug 2015

REFERENCES

  • Bowers DC, Nathan PC, Constine L, et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. Lancet Oncol. 2013;14:e321–e328.
  • Pettorini BL, Park YS, Caldarelli M, et al. Radiation-induced brain tumours after central nervous system irradiation in childhood: a review. Childs Nerv Syst. 2008;24:793–805.
  • von Hoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91. Eur J Cancer. 2009;45:1209–1217.
  • Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro Oncol. 2013;15:97–103.
  • Broniscer A, Ke W, Fuller CE, Wu J, Gajjar A, Kun LE. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer. 2004;100:2246–2252.
  • Maule M, Scelo G, Pastore G, et al. Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. Eur J Cancer. 2008;44:830–839.
  • Peterson KM, Shao C, McCarter R, MacDonald TJ, Byrne J. An analysis of SEER data of increasing risk of secondary malignant neoplasms among long-term survivors of childhood brain tumors. Pediatr Blood Cancer. 2006;47:83–88.
  • Strodtbeck K, Sloan A, Rogers L, et al. Risk of subsequent cancer following a primary CNS tumor. J Neurooncol. 2013;112:285–295.
  • MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neuro-oncology. 2011;13:1049–1058.
  • Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer. 2010;116:705–712.
  • Wolff JE, Kortmann RD, Wolff B, et al. High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study. J Neuro-oncol. 2011;102:433–442.
  • Wolff JE, Molenkamp G, Westphal S, et al. Oral trofosfamide and etoposide in pediatric patients with glioblastoma multiforme. Cancer. 2000;89:2131–2137.
  • Wolff JE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol. 2006;79:315–321.
  • Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2006;352:978–986.
  • Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
  • Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12:559–567.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.